itacitinib + epacadostat

**Itacitinib + epacadostat** is an investigational oral combination therapy for cancer, consisting of two small molecules: itacitinib (a selective Janus kinase 1 (JAK1) inhibitor) and epacadostat (a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor). Itacitinib disrupts cytokine-mediated signaling involved in immune cell function, while epacadostat blocks the metabolism of tryptophan into kynurenine, a pathway tumors exploit to induce immunosuppression in the tumor microenvironment. The combination has been studied in phase I trials for advanced or metastatic solid tumors, where it showed some tumor immune infiltration effects but no objective tumor responses. The development was primarily undertaken by Incyte. Both drugs act to modulate immune responses—a targeted strategy within cancer immunotherapy[1][3][4].